Roche: anti-cancer drug shows benefit in study.
(CercleFinance.com) - Roche's anti-cancer drug Alecensa significantly reduced the risk of disease worsening or death in patients with advanced ALK-positive lung cancer, according to data presented on Wednesday.
A global phase III study showed that Alecensa reduced the risk of the disease worsening or death (progression-free survival) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer, who had progressed following treatment with platinum-based chemotherapy and crizotinib, Roche said.
The results provide further evidence of the efficacy of Alecensa and support access for patients with ALK-positive lung cancer, the company added.
The data will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress on Monday 11 September.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
A global phase III study showed that Alecensa reduced the risk of the disease worsening or death (progression-free survival) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer, who had progressed following treatment with platinum-based chemotherapy and crizotinib, Roche said.
The results provide further evidence of the efficacy of Alecensa and support access for patients with ALK-positive lung cancer, the company added.
The data will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress on Monday 11 September.
Copyright (c) 2017 CercleFinance.com. All rights reserved.